|
|
|
 |
Search published articles |
 |
|
Showing 3 results for Farzad Najafipour (MD)
Farzad Najafipour (md), Roohangiz Sari Sorkhabi (md), Navideh Haji Aghai (gp), Masoomeh Zareizadeh (md), Amir Bahrami (md),
Volume 10, Issue 3 (10-2008)
Abstract
Background and Objective: Thalassemia major is a genetic disorder. Blood transfusion is critical for survival in these patients. Over the course of the past two and three decade’s hyper transfusion therapy in these patients has increased significant improvement in life expectancy and quality of life. Unfortunately this type of therapy increased the frequency of complication due to iron overloud. The aim of this study was to evaluate the prevalencey of diabetes, impaired fasting glucose and impaired glucose tolerance in patients with thalassemia major, with 10-27 years of age in Tabriz. Materials and Methods: This descriptive study was done on 56 patients between 10-27 years of age with thalassemia major. The demographic informaiton theraputic regiment, the age of first trasfussion. The level of blood transfusion, the history and dosage of familial history of diabetes, Fe, TIBC, ferritin levels were assessed and recorded. For each patient glucose tolerance test, blood glucose level are performed. Results: In this study prevalence of diabetes mellitus, impaired fasting glucose and impaired glucose tolerance test were found in 8.9%, 28.6% and 7.1% of patients respectively. Conclusion: This study showed that despite recent therapy with Desferal in the management of beta-thalassemia major, the risk of secondary endocrine dysfunction remains high. Prevalence of diabetes mellitus, impaired fasting glucose and impaired glucose tolerance test are greater than general population. Endocrine evaluation in patients with thalassemia major must be carried out regularly especially in those patients over the age of 10 years.
Nasser Aghamohammadzadeh (md), Farzad Najafipour (md), Akbar Aliasgharzadeh (md), Amir Bahrami (md), Mitra Niafar (md), Majid Mobasseri (md), Mehdi Amiri (md), Leila Baghlar (md),
Volume 11, Issue 1 (3-2009)
Abstract
Background and Objective: Diabetes mellitus is the most frequent cause of chronic renal failure. Microalbuminuria is the first clinically important sign of renal impairment in diabetes mellitus. The main pathophysiology of diabetic nephropathy is not understood. This study was done on 100 patients with type 2 diabetes for determination of the prevalence of diabetic nephropathy with urine albumin assay in Sina Hospital in Tabriz, North-West of Iran. Materials and Methods: In this discriptive study, 100 patients with type 2 diabetes whome consecutively referred to Endocrine and Diabetes Clinic of Sina Medical Center in Tabriz were enrolled. At the first visit clinical and biochemical parameters such as systolic and diastolic blood pressure, age, sex, body weight, length, body mass index, FBS, HbA1C, plasma creatinine, urine microalbumin and urinary creatinine were measured. FBS, HbA1C, plasma creatinine, urine microalbumin and urinary creatinine measurements repeated every 2 months up to three times during the study. Patients with confounding factors such as uncontrolled hypertension, urinary tract infection, congestive heart failure and hyperlipidemia were excluded. Results: The prevalence of diabetic nephropathy was 36% in our patients. There were not statistically significant differences in age and sex and diastolic – systolic blood pressure and creatinine between nephropathy and, non-nephropathy groups. There was significant differences in body mass index between two sex groups, females were more obese than males. Mean duration of diabetes in diabetic nephropathy group and in diabetic patients without nephropathy were 12.4±8.1 and 9.1±5.5 respectively (P<0.05). Comparison of HbA1c, FBS and drugs used for diabetes treatment were not significant differences between these groups. Conclusion: This study showed that prevalence of diabetic nephropathy was higher than other studies, although there were not significant differences between FBS, HbA1c and hypertension in patients with and without diabetic nephropathy.
Nasser Aghamohammadzadeh (md), Farzad Najafipour (md), Amir Bahrami (md), Mitra Niafar (md), Leila Baglar (md), Hamideh Hajiegrary (md), Akbar Aliasgharzadeh (md), Majid Mobasseri (md),
Volume 11, Issue 2 (7-2009)
Abstract
Background and Objective: Osteoporosis is the most common metabolic bone disease that characterized by reduced bone strength. The aim of this study was to evaluate the prevalence of effective factors in decreased bone density and secondary causes of osteoporosis.
Materials and Methods: This descriptive cross sectional study was done on 105 patients (76 female and 29 male) suffering from osteoporosis, evaluated in the endocrinology Department of Sina hospital, Tabriz- Iran from March 2003 to March 2006. Past medical history clinical symptoms and biochemical results were of patients. Data analyzed using SPSS-14 and chi square test.
Results: Osteoporosis and osteopenia were seen in 55% and 45% of patients with reduced bone density, respectively. Daily calcium intake in patients with less than 400 mg, between 400-1000 mg and more than 1000 mg were 63.8%, 31.9% and 3.4%, respectively. The mean±SD of sera calcium and vitamin D level were 9.5±0.6 mg/dl, 45±37.1 nmol/l respectively. 61.2% of patients had vitamin D deficiency. 33% of patients had secondry osteoprosis. Among the patient with primary osteoprosis 11.3% afflicted to hyper claciuria.
Conclusion: This study showed that decresing bone density was more prominate in women. The rate of daily calcium intake among patients were low. It is sugested these patients osteoprosis could be prevented by consumption food nutrient rich in calcium and vitamin D suplementation.
|
|
